{
    "id": 529,
    "fullName": "MPL wild-type",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "Wild-type MPL indicates that no mutation has been detected within the MPL gene.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 4352,
        "geneSymbol": "MPL",
        "terms": [
            "MPL",
            "C-MPL",
            "CD110",
            "MPLV",
            "THCYT2",
            "THPOR",
            "TPOR"
        ]
    },
    "variant": "wild-type",
    "createDate": "05/13/2014",
    "updateDate": "09/27/2018",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 5788,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Jakafi (ruxolitinib) and ZSTK474 synergistically inhibited growth of transformed cell lines over expressing wild-type Mpl and JAK2 V617F in cell culture (PMID: 24251790).",
            "molecularProfile": {
                "id": 21621,
                "profileName": "JAK2 V617F MPL wild-type"
            },
            "therapy": {
                "id": 3926,
                "therapyName": "Ruxolitinib + ZSTK474",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5156,
                    "pubMedId": 24251790,
                    "title": "Combination treatment for myeloproliferative neoplasms using JAK and pan-class I PI3K inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24251790"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5794,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Jakafi (ruxolitinib) and Pictilisib (GDC-0941) synergistically inhibited growth of transformed cell lines over expressing wild-type Mpl and JAK2 V617F in cell culture (PMID: 24251790).",
            "molecularProfile": {
                "id": 21621,
                "profileName": "JAK2 V617F MPL wild-type"
            },
            "therapy": {
                "id": 3927,
                "therapyName": "Pictilisib + Ruxolitinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5156,
                    "pubMedId": 24251790,
                    "title": "Combination treatment for myeloproliferative neoplasms using JAK and pan-class I PI3K inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24251790"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5800,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Jakafi (ruxolitinib) and BEZ235 synergistically inhibited growth of transformed cell lines over expressing wild-type Mpl and JAK2 V617F in cell culture (PMID: 24251790).",
            "molecularProfile": {
                "id": 21621,
                "profileName": "JAK2 V617F MPL wild-type"
            },
            "therapy": {
                "id": 3928,
                "therapyName": "BEZ235 + Ruxolitinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5156,
                    "pubMedId": 24251790,
                    "title": "Combination treatment for myeloproliferative neoplasms using JAK and pan-class I PI3K inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24251790"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5806,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Jakafi (ruxolitinib) and TGX-221 synergistically inhibited growth of transformed cell lines over expressing wild-type Mpl and JAK2 V617F in cell culture (PMID: 24251790).",
            "molecularProfile": {
                "id": 21621,
                "profileName": "JAK2 V617F MPL wild-type"
            },
            "therapy": {
                "id": 3929,
                "therapyName": "Ruxolitinib + TGX-221",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5156,
                    "pubMedId": 24251790,
                    "title": "Combination treatment for myeloproliferative neoplasms using JAK and pan-class I PI3K inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24251790"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13707,
            "approvalStatus": "Guideline",
            "evidenceType": "Prognostic",
            "efficacyEvidence": "The presence of concurrent wild-type JAK2, MPL, and CALR in myelofibrosis patients is associated with inferior leukemia-free survival compared to patients with JAK2 and/or CALR mutations, and is associated with inferior overall survival when compared to patients with CALR mutations (NCCN.org).",
            "molecularProfile": {
                "id": 29392,
                "profileName": "CALR wild-type JAK2 wild-type MPL wild-type"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 4971,
                "name": "myelofibrosis",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        }
    ],
    "molecularProfiles": [
        {
            "id": 588,
            "profileName": "MPL wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 21621,
            "profileName": "JAK2 V617F MPL wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29392,
            "profileName": "CALR wild-type JAK2 wild-type MPL wild-type",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}